GLP-1 receptor agonist use appeared linked to significantly reduced all-cause mortality among people with sickle cell disease ...

The discussion surrounding GLP-1 medications needs to change to one that emphasizes science-based research and compassion.

MEDVi, a telehealth platform serving more than 100,000 patients, today announced an expanded physician-led program ...

By reinforcing exercise, health care providers can ensure that GLP-1 therapy leads to weight loss, sustains muscle mass, and ...

With the supply of GLP-1 medications finally stabilizing as their use skyrocketed 600% among Americans from 2018 to 2024, the pharmaceutical landscape for anti-obesity medications is now poised to ...

The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3) to evaluate weekly ribupatide ...

Two of the most closely watched Alzheimer clinical trials of the decade have delivered a sobering verdict: GLP-1 drugs that revolutionized diabetes and weight loss did not slow the disease’s ...

“Orforglipron and retatrutide from Eli Lilly exemplify the next generation of metabolic therapies: oral formulations that promise improved adherence, triple-hormone mechanisms that deliver superior ...

LMNT reports that GLP-1 medications for obesity and diabetes may lead to electrolyte imbalances, highlighting hydration ...

Discover the top five ingredient trends driving GLP-1 innovation in the food and beverage industry. From proteins and fibers ...